119th Congress · introduced in the House · Jul 23, 2025
End the Vaccine Carveout Act
Official title from Congress.gov
Latest action (Jul 23, 2025): Referred to the House Committee on Energy and Commerce.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in House (Jul 23, 2025)
End the Vaccine Carveout Act
This bill removes liability protections for manufacturers and administrators for vaccine-related injuries, and removes limitations on bringing civil actions for vaccine-related injuries or seeking compensation, under the National Vaccine Injury Compensation Program (VICP). It also excludes COVID-19 vaccines from liability protections under the Countermeasures Injury Compensation Program (CICP).
Under current law, the VICP provides compensation for alleged injuries caused by certain routinely administered vaccines. Individuals generally may not file a civil action in court unless a VICP claim is filed and the resulting judgement is rejected. The VICP also limits the types of claims and amount of damages that may be sought (e.g., no liability for unavoidable side effects or failure to directly warn), and it imposes deadlines for filing claims. The bill removes the requirement to first file a claim under the VICP before pursuing a civil action, so individuals alleging vaccine-related injuries may choose to either bring a civil action or utilize the VICP. It also removes the restrictions on the types of civil actions and damages. The bill also removes the deadlines for filing claims under the VICP and applies this change retroactively.
Additionally, under current law, the CICP provides compensation for alleged injuries caused by certain medical countermeasures during public health emergencies, including COVID-19 vaccines. The bill excludes COVID-19 vaccines from being considered as medical countermeasures. Therefore, under the bill, individuals may file civil actions against manufacturers of COVID-19 vaccines rather than filing claims under the CICP.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
No matching lobbying reports found within coverage